FDA FY 2024 Budget Includes 10% Funding Boost, But No Movement On Diagnostics

The FDA requested a 10% increase in budget authority for FY 2024, but diagnostic reform was left out of the proposal. 

• Source: Shutterstock

The Food and Drug Administration’s $7.2bn FY 2024 budget is an increase of $372m (10%) in budget authority from last year but does not include any indication the agency is looking for funds for the much-anticipated diagnostics reform.

This was a surprise to some because the FDA often uses budget proposals to highlight its priorities, and regulators in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

More from Policy & Regulation

Whoops! FDA Says Company Marketed Unauthorized Device. The Company Says The FDA Is Wrong

 

A recent FDA warning letter claims a Boston firm that specializes in wearable technology marketed a blood pressure device without agency approval. The company rejects the assertion and says the agency is out of step with federal law.

With CMS Coverage Established, Medtronic Looks To Next Steps For Renal Denervation

 
• By 

US Medicare has proposed national coverage of renal denervation for patients with uncontrolled hypertension. The treatment is seeing other advances as well, with Medtronic piloting a longer catheter and a multi-organ approach and a blood test to identify the best candidates fresh on the

House Bill Calls For ‘Non-Flushable’ Label On Personal Wipes

 

The US House of Representatives passes legislation requiring manufacturers of non-flushable wet wipes to label products as ‘non-flushable," a move endorsed by the Personal Care Products Council.